Celcuity
Forecast impact
Track in portfolio
Price chart
Description
Company and Business Model
Celcuity is a healthcare company focused on developing innovative cancer therapies. Its core product is the Celcuity platform, which utilizes a proprietary technology to identify and target specific cancer cell types. The company primarily operates in the oncology segment, generating revenue through partnerships and collaborations with pharmaceutical companies for drug development and clinical trials.
Investment Profile
The investment profile of Celcuity is more aligned with growth investors, given its focus on developing new therapies and potential market expansion. The company does not currently offer dividends, and its financial performance indicates a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, with moderate liquidity reflecting the stock's trading characteristics.
Fundamental metrics (experimental) Updated: 2026-09-10
- EPS (TTM) — earnings per share for the last 12 months, $
- -4.29
- EPS surprise
- -24.1%
- 20d volatility
- 2.5%
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-29 | Hold | Sell | Weak fundamentals and negative momentum signal high risk. |
| 2026-08-20 | Sell | Hold | Weak fundamentals with mixed momentum signals. |
| 2026-07-09 | Hold | Sell | Weak fundamentals and high volatility raise concerns. |
| 2026-06-29 | Sell | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-06-03 | Hold | Sell | scenario_deterioration |
| 2026-05-08 | — | Hold | Weak fundamentals with high volatility and uncertain market signals. |
| 2026-05-05 | — | Hold | Компания демонстрирует значительный рост цен за последние месяцы, что указывает на позитивные ожидания рынка. Однако отрицательный EPS и высокая волатильность требуют осторожности. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-08-17 | Guggenheim | Target Raised | — → 175 | 92 |
| 2026-08-14 | Needham | Target Lowered | — → 140 | 86.6 |
| 2026-07-15 | Craig-Hallum | Target Raised | 171 → 178 | 90.09 |
| 2026-07-15 | H.C. Wainwright | Target Raised | 145 → 155 | 111.05 |
| 2026-06-03 | Craig-Hallum | Target Lowered | 189 → 171 | 89.1199 |
| 2026-06-03 | H.C. Wainwright | Target Lowered | 185 → 145 | 91.42 |
| 2026-06-03 | Wells Fargo | Target Lowered | — → 166 | 91.42 |
| 2026-06-02 | Leerink Partners | Target Lowered | — → 155 | 93.37 |
| 2026-05-28 | Macquarie | Update | — → 160 | 133.97 |
| 2026-05-18 | H.C. Wainwright | Target Raised | 165 → 185 | 137.68 |
| 2026-05-15 | Wells Fargo | Target Raised | 150 → 183 | 134.72 |
| 2026-05-04 | Craig-Hallum | Target Raised | 141 → 189 | 146.235 |
| 2026-05-04 | Guggenheim | Target Raised | 135 → 165 | 125.65 |
| 2026-05-04 | Needham | Target Raised | 122 → 157 | 125.65 |
| 2026-05-04 | Stifel Nicolaus | Target Raised | 125 → 150 | 125.65 |
| 2026-05-04 | H.C. Wainwright | Rating Upgraded | — → 165 | 125.65 |
| 2026-03-26 | Craig-Hallum | Target Raised | 108 → 141 | 114.81 |
| 2026-03-12 | Wolfe Research | Update | — → 110 | 110.7315 |
| 2026-03-10 | Needham | Target Raised | — → 122 | 115.94 |
| 2025-12-12 | Wells Fargo | Update | — → 126 | 100.7 |
| 2025-10-22 | H.C. Wainwright | Target Raised | 66 → 77 | 65.22 |
News Page 1 of 1
Nothing yet